Alterity Therapeutics to Showcase MSA Research at Key Conferences in May 2026
Event summary
- Alterity Therapeutics will present data on its MSA development program at three medical conferences in May 2026.
- Oral presentation on iron accumulation in early MSA at ISMRM conference in Cape Town on May 12, 2026.
- Poster presentation on Phase 2 trial results of ATH434 at MDSANZ conference in Sydney from May 15-17, 2026.
- CEO David Stamler to present ATH434 clinical update and Phase 3 planning at MSA Symposium in London on May 18, 2026.
The big picture
Alterity Therapeutics is advancing its lead asset ATH434 through critical clinical stages, with upcoming presentations providing key insights into its potential as a disease-modifying treatment for Multiple System Atrophy. The company's focus on MSA, a rare and rapidly progressive neurodegenerative disease, positions it in a niche market with high unmet medical need. Successful Phase 3 initiation would be a significant milestone in Alterity's development pipeline.
What we're watching
- Clinical Validation
- Whether the Phase 2 trial data for ATH434 will demonstrate sufficient efficacy to support Phase 3 planning.
- Regulatory Pathway
- The timeline for Alterity to initiate its Phase 3 pivotal trial in MSA.
- Market Positioning
- How Alterity positions ATH434 against potential competitors in the MSA treatment landscape.
Related topics